You just read:

Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric Cancer

News provided by

Daiichi Sankyo Company, Limited

29 Apr, 2019, 23:30 BST